Emulate, Inc.
PrivateLast Round
Series F
Mar 1, 2024
Total Funding Raised
$271.3M
Company Overview
Emulate, Inc. is a biotechnology company that develops and commercializes Organ-on-a-Chip technology to recreate human biology for drug discovery, safety testing, and disease research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Emulate, Inc. Comparables
Compare Emulate, Inc. with similar companies based on industry and business-model similarity.
Emulate, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series F | Mar 1, 2024 | ||||
| Series E | Sep 7, 2021 | ||||
| Debt | Mar 23, 2020 | ||||
| Series D | Aug 16, 2019 | ||||
| Series C | Jul 24, 2018 | ||||
Grant | Jun 20, 2017 |
Key People
Founding team and executive leadership
Emulate, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SciFi Ventures | Series C |
| Perceptive Advisors | Series E |
| Founders Fund | Series D, Series C |
| +ND Capital | Series B, Series B Extension, Series A |
| Northpond Ventures | Series D, Series E |
| ALS Investment Fund | Series D, Series C |
| Cedars Sinai Health Ventures | Series B, Series A, Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 13, 2026
Liver-Chip BioKit validated under FDA's ISTAND program.
- Feb 27, 2026
Attended SLAS 2026 and won a New Product Award.
Recent news
Latest coverage and updates
- has_valuationSep 18, 2026
Emulate, Inc. is closing in on a $700 million seed round at a $3.7B valuation led by Index Ventures and Lightspeed in Sep '26.
Emulate, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Emulate, Inc.'s valuation, stock price, and market status.
Is Emulate, Inc. a public or private company?
Emulate, Inc. is a private company.
What is the current stock price of Emulate, Inc.?
Emulate, Inc. is a private company, so its shares have no public market price. Caplight tracks Emulate, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Emulate, Inc. worth (valuation)?
Valuation information for Emulate, Inc. is not publicly available.
Can I buy Emulate, Inc. stock?
Emulate, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Emulate, Inc.'s last funding round?
Emulate, Inc.'s most recent funding round was Series F on March 1, 2024.
Who are the main investors in Emulate, Inc.?
Key investors in Emulate, Inc. include Perceptive Advisors, Founders Fund, +ND Capital, Northpond Ventures, OS Fund.
Will Emulate, Inc. IPO soon?
No public IPO plans have been announced for Emulate, Inc..
How can I track Emulate, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Emulate, Inc.'s shares on secondary markets.